- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05647564
PET/CT Caracterización de la Resistencia al Tratamiento
Caracterización PET/CT de la resistencia al tratamiento de terapias dirigidas a AR en CPRCm
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
There are two groups, or cohorts, in this study. Participants are assigned to Cohort A if they have advanced prostate cancer and are scheduled to start a second-generation AR-targeted therapy (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed radiotherapy (e.g. Lu177-PSMA radio-ligand therapy. Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.
There are two medical imaging scans that will be done for research purposes in this study. One is called 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and the other is prostate-specific membrane antigen positron emission tomography (PSMA PET). These scans are done simultaneously with computed tomography (CT) scanning. Participants will be scheduled to have 6 scans, 3 FDG PET/CT scans and 3 PSMA PET/CT scans.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Cancer Connect
- Número de teléfono: 800-622-8922
- Correo electrónico: clinicaltrials@cancer.wisc.edu
Ubicaciones de estudio
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53705
- Reclutamiento
- University of Wisconsin
-
Contacto:
- Cancer Connect
- Número de teléfono: 800-622-8922
- Correo electrónico: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- John Floberg, MD, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically proven adenocarcinoma of the prostate.
- At least 1 radiographic metastases as seen on conventional CT imaging or bone scan
- Progressive prostate cancer as evident by at least two separate increase in PSA over nadir, and absolute PSA value at least 2 ng/ml (INTRINSIC RESISTANCE COHORT, ARSI patients ONLY)
- Patients must be candidate for a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide), or Lu177-PSMA radioligand therapy (INTRINSIC RESISTANCE COHORT ONLY)
- Men of age >18 years.
- Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging
- Patients must be informed of the exploratory nature of the study and its potential risks, and must sign IRB-approved consent form indicating such understanding.
- Life-expectancy at least 12 months
- Patients currently receiving a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide) and must have had 1) PSA decline on treatment and 2) now have PSA increase over nadir while still on treatment (patients must be registered within 12 weeks of first documented PSA increase) (ACQUIRED RESISTANCE COHORT ONLY)
Exclusion Criteria:
- Must not have uncontrolled diabetes (fasting blood sugar > 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours prior to FDG PET scan)
- Prior treatment with second-generation AR inhibitor for prostate cancer in the metastatic disease setting (prior second-generation AR inhibitor in the neoadjuvant or adjuvant setting is permitted unless patient developed progression while on treatment) (INTRINSIC RESISTANCE COHORT, AR-INHIBITOR GROUP ONLY)
- Pain or clinical symptoms from metastatic prostate cancer requiring opioid analgesics
- Known neuro-endocrine prostate cancer
- Prior radioisotope therapy for castration-resistant prostate cancer
- To avoid the possibility of unintended coercion, vulnerable populations such as incarcerated subjects, subjects unable to provide their own informed consent and non-English speaking patients will not be considered
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Intrinsic Resistance Cohort (Cohort A)
Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies . |
Imaging scan Imaging scan |
|
Otro: Acquired Resistance Cohort (Cohort B)
Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels. |
Imaging scan Imaging scan |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Characterize intrinsic resistance based on FDG and PSMA PET through change in individual lesion update levels.
Periodo de tiempo: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which less activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Periodo de tiempo: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Periodo de tiempo: 12 weeks to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
12 weeks to 36 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Periodo de tiempo: Baseline to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 36 weeks
|
|
Characterize acquired resistance at the time of progression
Periodo de tiempo: Baseline to 36 weeks
|
Percentage and absolute changes in individual lesion update levels (ΔiSUVtotal) will be calculated. |
Baseline to 36 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to PSA progression
Periodo de tiempo: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to PSA progression. PSA progression will be 25% increase and >2 ng/mL above PSA nadir |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
Periodo de tiempo: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to radiographic progression. Time to radiographic progression will be defined as the number of days to confirmed radiographic progression using Prostate Cancer WorkingGroup 3 (PCWG3) criteria. |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time duration on treatment
Periodo de tiempo: Up to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict duration of treatment. Duration of treatment will be defined as the time from treatment start, to treatment discontinuation (and reason for discontinuation) using PCWG3 criteria. |
Up to 36 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Glenn Liu, MD, University of Wisconsin, Madison
- Investigador principal: Robert Jeraj, PhD, University of Wisconsin, Madison
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2022-0910
- A534260 (Otro identificador: UW Madison)
- 2022-0910 (Otro identificador: UW Madison)
- SMPH/MEDICINE/HEM-ONC (Otro identificador: UW Madison)
- NCI-2022-09580 (Identificador de registro: NCI)
- Protocol Version 8/1/2026 (Otro identificador: UW Madison)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .